NPPA Fixes Retail Price of 51 Formulations, Details
New Delhi: Through a recent notification, the National Pharmaceutical Pricing Authority (NPPA), the Ministry of Chemicals and Fertilizers, Government of India, has fixed the retail price of 51 formulations, including pain killers, pulmonary drugs, and those used to treat high blood pressure, type 2 diabetes, and bacterial infections.This came in line with the decision of the 116th...
New Delhi: Through a recent notification, the National Pharmaceutical Pricing Authority (NPPA), the Ministry of Chemicals and Fertilizers, Government of India, has fixed the retail price of 51 formulations, including pain killers, pulmonary drugs, and those used to treat high blood pressure, type 2 diabetes, and bacterial infections.
This came in line with the decision of the 116th Authority meeting dated 6.09.2023, where the authority discussed the new drug applications for price fixation under para 5 and 15 of drugs prices control order, 2013 (DPCO 2013).
These include Synokem pharmaceutical/Torrent Pharmaceutical's fixed dose combination Rosuvastatin plus Clopidogrel Capsules, Daiwik Pharmasphere/ Aristo Pharmaceuticals' Diclofenac Diethylamine, Methyl Salicylate and Menthol Gel, Exemed Pharmaceuticals/Abbott Healthcare's Linagliptin and Metformin Hydrochloride Tablets, Sai Primus Life Biotech/Primus Remedies' Linagliptin plus Metformin Hydrochloride Tablet.
The list further includes, Skymap Pharmaceuticals' Linagliptin plus Metformin Hydrochloride Tablet, Skymap Pharmaceuticals/ Glensmith Labs' Linagliptin plus Metformin Hydrochloride Tablet, Skymap Pharmaceuticals' Linagliptin plus Metformin Hydrochloride Tablet, Lucent Biotech/Torrent Pharmaceutical's Pantoprazole Sodium (EC) & Levosulpiride (SR) Capsules.
The retail prices for the fixed-dose combinations of Linagliptin and Metformin Hydrochloride Tablets manufactured and marketed by Macleods Pharmaceuticals, Linagliptin and Metformin Hydrochloride (ER) Tablets manufactured and marketed by Synokem Pharmaceuticals and Cipla, and Cefuroxime Axetil and Potassium Clavulanate FDC Tablets manufactured and marketed by Hetero Labs and Sun Pharmaceuticals, have also been set.
This comes in exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (NPPA), has fixed, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
1 | Rosuvastatin & Clopidogrel Capsules | Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg (as Pellets) Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets) | 1 Capsule | M/s Synokem Pharmaceuticals Ltd / M/s Torrent Pharmaceuticals Limited | 18.95 |
2 | Diclofenac Diethylamine, Methyl Salicylate and Menthol Gel | Composition: Diclofenac Diethylamine IP 2.32 % w/w eq. to Diclofenac Sodium IP 2.0 % w/w Methyl Salicylate IP 10 % w/w Menthol IP 5 % w/w | 1 Gram | M/s Daiwik Pharmasphere Pvt. Ltd. / M/s Aristo Pharmaceuticals Pvt. Ltd. | 4.08 |
3 | Linagliptin and Metformin Hydrochloride Tablets | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 500mg | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Abbott Healthcare Pvt. Ltd. | 8.97 |
4 | Linagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 850mg | 1 Tablet | M/s Sai Primus Life Biotech Private Limited / M/s Primus Remedies Pvt. Ltd. | 12.18 |
5 | Linagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 1000mg | 1 Tablet | M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s Glensmith Labs Pvt. Ltd. | 9.60 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
6 | Linagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 500mg | 1 Tablet | M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s Glensmith Labs Pvt. Ltd. | 8.97 |
7 | Linagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 500mg | 1 Tablet | M/s Skymap Pharmaceuticals Pvt. Ltd. | 8.97 |
8 | Linagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 1000mg | 1 Tablet | M/s Skymap Pharmaceuticals Pvt. Ltd. | 9.60 |
9 | Linagliptin and Metformin Hydrochloride Tablets | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 1000mg | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Abbott Healthcare Pvt. Ltd. | 9.60 |
10 | Pantoprazole Sodium (EC) & Levosulpiride (SR) Capsules | Each Hard gelatine capsule contains: Pantoprazole Sodium Sesquihydrate IP eq. to Pantoprazole 40mg (As Enteric Coated Pellets) Levosulpiride 75mg (As Sustained Release Pellets) | 1 Capsule | M/s Lucent Biotech Limited / M/s Torrent Pharmaceuticals Ltd. | 15.96 |
11 | Budesonide and Formoterol Fumarate | Each 2 ml respule contains: Budesonide IP 1mg Formoterol Fumarate Dihydrate eq. to Formoterol Fumarate 20 mcg | Per 2 ml | M/s Axa Parenterals Ltd./ M/s J.B. Chemicals & Pharmaceuticals Ltd. | 56.20 |
12 | Itraconazole Capsules (Supra- Bioavailable Formulation) | Each Hard gelatine capsule contains: (Supra-Bioavailable formulation) Itraconazole IP 130mg | 1 Capsule | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Dr. Reddy's Laboratories Limited | 19.30 |
13 | Linagliptin + Metformin Hydrochloride Extended Release Tablet | Each film coated bilayer tablet contains: Linagliptin 2.5mg Metformin Hydrochloride (As extended release)IP 1000mg | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Intas Pharmaceuticals Ltd. | 9.60 |
14 | Linagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 500mg | 1 Tablet | M/s Macleods Pharmaceuticals Ltd. | 8.97 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
15 | Linagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 1000mg | 1 Tablet | M/s Macleods Pharmaceuticals Ltd. | 9.60 |
16 | Linagliptin + Metformin Hydrochloride (ER) Tablet | Each film coated bilayered tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 1000mg (as Extended release) | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Cipla Ltd. | 9.60 |
17 | Itraconazole Capsules (Supra- Bioavailable Formulation) | Each Hard gelatine capsule contains: (Supra-Bioavailable formulation) Itraconazole IP 65mg | 1 Capsule | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Dr. Reddy's Laboratories Limited | 10.81 |
18 | Diclofenac Potassium & Metaxalone Tablets | Each uncoated tablet contains: Diclofenac Potassium IP 50mg Metaxalone USP 400mg | 1 Tablet | M/s Windlas Biotech Limited / M/s Intas Pharmaceuticals Ltd. | 15.08 |
19 | Cefuroxime Axetil & Potassium Clavulanate Tablets | Each film coated tablet contains: Cefuroxime Axetil IP eq. to Cefuroxime 500mg Potassium Clavulanate Diluted IP Eq. to Clavulanic Acid 125mg | 1 Tablet | M/s Hetero Labs Limited / M/s Sun Pharmaceuticals Industries Limited | 55.23 |
20 | Levosalbutamol and Ipratropium Bromide respule solution | Each 2.5ml contains: Levosalbutamol Sulphate IP eq. to Levosalbutamol 1.25mg Ipratropium Bromide IP eq. to Ipratropium (anhydrous) 500mcg | 1 ML | M/s AXA Parenterals Ltd. / M/s Mankind Pharma Ltd. | 5.49 |
21 | Moxifloxacin Eye Drops | Composition: Moxifloxacin hydrochloride IP eq. to Moxofloxacin 0.5%w/v Preservative : Benzalkonium Chloride Solution IP 0.02% w/v | 1 ML | M/s East African (India) Overseas / M/s Torrent Pharmaceuticals Limited | 17.00 |
22 | Pantoprazole Dual Release Gastro Resistant Tablets | Each Dual Release Gastro Resistant Tablet Contains: Pantoprazole Sodium IP eq. to Pantoprazole 80mg | 1 Tablet | M/s Pure & Cure Healthcare Pvt. Ltd. / M/s Mankind Pharma Ltd. | 15.30 |
23 | Telmisartan, Chlorthalidone & Cilnidipine tablets | Each film coated tablet contains: Telmisartan IP 40mg Chlorthalidone IP 6.25mg Cilnidipine IP 10mg | 1 Tablet | M/s Macleods Pharmaceuticals Ltd. | 13.05 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
24 | Povidone Iodine Gargle | Composition: Povidone Iodine IP 0.5% w/v (available Iodine 0.05% w/v) | 1 ml | M/s Pontika Aerotech Limited / M/s Emcure Pharmaceuticals Limited | 0.70 |
25 | Teneligliptin, Pioglitazone and Metformin Hydrochloride (as Sustained Release) Tablets | Each Film coated bilayered tablet contains: Teneligliptin Hydrobromide Hydrate IP eq. to Teneligliptin 20mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15mg Metformin Hydrochloride IP 500mg (as Sustained Release) | 1 Tablet | M/s Synokem Pharmaceuticals Limited / M/s Micro Labs Limited | 16.07 |
26 | Teneligliptin, Pioglitazone and Metformin Hydrochloride (as Sustained Release) Tablets | Each Film coated bilayered tablet contains: Teneligliptin Hydrobromide Hydrate IP eq. to Teneligliptin 20mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15mg Metformin Hydrochloride IP 1000mg (as Sustained Release) | 1 Tablet | M/s Synokem Pharmaceuticals Limited / M/s Micro Labs Limited | 17.85 |
27 | Sitagliptin, Pioglitazone and Metformin Hydrochloride (Sustained Released) Tablet | Each film coated Bilayered Tablet Contain: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydrochloride IP 500mg (Sustained Release Form) | 1 Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Intas Pharmaceuticals Ltd. | 16.06 |
28 | Sitagliptin, Pioglitazone and Metformin Hydrochloride (Sustained Released) Tablet | Each film coated Bilayered Tablet Contain: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydrochloride IP 500mg (Sustained Release Form) | 1 Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Eris Lifesciences Limited | 16.06 |
29 | Sitagliptin, Pioglitazone and Metformin Hydrochloride (Sustained Released) Tablet | Each film coated Bilayered Tablet Contain: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydrochloride IP | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Intas Pharmaceuticals Ltd. | 16.06 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
500mg (Sustained Release Form) | |||||
30 | Sitagliptin, Pioglitazone and Metformin Hydrochloride (Sustained Released) Tablet | Each film coated Bilayered Tablet Contain: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydrochloride IP 500mg (Sustained Release Form) | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Emcure Pharmaceuticals Ltd. | 16.09 |
31 | Sitagliptin, Pioglitazone and Metformin Hydrochloride (Sustained Released) Tablet | Each film coated Bilayered Tablet Contain: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydrochloride IP 500mg (Sustained Release Form) | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s La Renon Healthcare Private Limited | 16.09 |
32 | Sitagliptin, Pioglitazone and Metformin Hydrochloride (Sustained Released) Tablet | Each film coated Bilayered Tablet Contain: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydrochloride IP 1000mg (Sustained Release Form) | 1 Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Intas Pharmaceuticals Ltd. | 17.13 |
33 | Sitagliptin, Pioglitazone and Metformin Hydrochloride (Sustained Released) Tablet | Each film coated Bilayered Tablet Contain: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydrochloride IP 1000mg (Sustained Release Form) | 1 Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Eris Lifesciences Limited | 17.13 |
34 | Sitagliptin, Pioglitazone and Metformin Hydrochloride (Sustained Released) Tablet | Each film coated Bilayered Tablet Contain: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydrochloride IP 1000mg (Sustained Release Form) | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Intas Pharmaceuticals Ltd. | 17.13 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
35 | Sitagliptin, Pioglitazone and Metformin Hydrochloride (Sustained Released) Tablet | Each film coated Bilayered Tablet Contain: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydrochloride IP 1000mg (Sustained Release Form) | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Emcure Pharmaceuticals Ltd. | 17.16 |
36 | Sitagliptin, Pioglitazone and Metformin Hydrochloride (Sustained Released) Tablet | Each film coated Bilayered Tablet Contain: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydrochloride IP 1000mg (Sustained Release Form) | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s La Renon Healthcare Private Limited | 17.16 |
37 | Dapagliflozin, Vildagliptin (As Sustained release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each film coated bilayer tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Vildagliptin (As Sustained release) IP 100mg Metformin Hydrochloride IP (as Sustained Release) 500mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Primus Remedies Pvt. Ltd. | 18.00 |
38 | Dapagliflozin, Vildagliptin (As Sustained release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each uncoated bilayer tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 5mg Vildagliptin (As Sustained release) IP 100mg Metformin Hydrochloride (as Sustained Release) IP 500mg | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Alkem Laboratories Limited | 16.29 |
39 | Dapagliflozin, Vildagliptin (As Sustained release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each film coated bilayer tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Vildagliptin (As Sustained release) IP 100mg Metformin Hydrochloride IP (as Sustained Release) 1000mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Primus Remedies Pvt. Ltd. | 19.00 |
40 | Dapagliflozin, Sitagliptin and Metformin | Each film coated tablet contains: Dapagliflozin Propanediol Monohydrate eq. to | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Alkem | 14.59 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Hydrochloride (ER) Tablets | Dapagliflozin 5mg Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg (As Extende Release form) | Laboratories Limited | |||
41 | Dapagliflozin, Sitagliptin and Metformin Hydrochloride (ER) Tablets | Each film coated tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 5mg Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 50mg Metformin Hydrochloride IP 500mg (As Extende Release form) | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Alkem Laboratories Limited | 13.62 |
42 | Linagliptin + Metformin Hydrochloride Extended Release Tablet | Each film coated bilayer tablet contains: Linagliptin 5mg Metformin Hydrochloride (As extended release) IP 1000mg | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Intas Pharmaceuticals Ltd. | 14.37 |
43 | Linagliptin + Metformin Hydrochloride (ER) Tablet | Each film coated bilayered tablet contains: Linagliptin 5mg Metformin Hydrochloride IP 1000mg (as Extended release) | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Cipla Ltd. | 14.37 |
44 | Linagliptin + Metformin Hydrochloride (ER) Tablet | Each film coated tablet contains: Linagliptin 5mg Metformin Hydrochloride (as Extended release) IP 1000mg | 1 Tablet | M/s Exemed Pharmaceuticals Ltd. / M/s Micro Labs Ltd. | 14.37 |
45 | Linagliptin + Metformin Hydrochloride (ER) Tablet | Each film coated bilayered tablet contains: Linagliptin 5mg Metformin Hydrochloride (as Extended release) IP 1000mg | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Torrent Pharmaceuticals Ltd. | 14.00 |
46 | Linagliptin + Metformin Hydrochloride (ER) Tablet | Each film coated bilayered tablet contains: Linagliptin 5mg Metformin Hydrochloride (as Extended release) IP 1000mg | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Lupin Limited | 14.37 |
47 | Metoprolol Succinate Extended Release, Amlodipine 5mg | Each film coated bilayered tablet contains: Metoprolol Succinate IP 47.50mg eq. to Metoprolol Tartrate 50mg (As Extended | 1 Tablet | M/s Ajanta Pharma Limited | 14.23 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
& Telmisartan Tablet | release) Amlodipine Besilate IP IP eq. to Amlodipine 5mg Telmisartan IP 40mg | ||||
48 | Ambroxol Hydrochloride, Salbutamol Sulphate, Guaiphenesin & Methol Liquid | Each 5ml contains: Ambroxol Hydrochloride IP 15mg Salbutamol Sulphate IP eq. to Salbutamol 1mg Guaiphenesin IP 50mg Methol IP 1mg | 1 ml | M/s Naxpar Pharma Pvt. Ltd. / M/s Geno Pharmaceuticals Pvt. Ltd. | 0.52 |
49 | Glimepiride & Lobeglitazone Sulfate tablet | Each uncoated Bilayer tablet contains: Lobeglitazone Sulfate 0.5mg Glimepiride IP 1mg | 1 Tablet | M/s Glenmark Pharmaceuticals Limited | 11.39 |
50 | Combikit of Clarithromycin Tablets IP, Esomeprazole Tablets IP & Amoxicillin Tablets USP | Each Strip contains: A. Clarithromycin Tablets IP 2 Tablets Each film coated tablet contains: Clarithromycin IP 500mg B. Esomeprazole Tablets IP 2 Tablets Each Enteric coated tablet contains: Esomeprazole Magnesium Trihydrate IP eq. to Esomeprazole 40mg C. Amoxicillin Tablets USP 2 Tablets Each Film coated tablet contains: Amoxycillin Trihydrate IP eq. to Amoxycillin 1000mg | Each Strip | M/s Malik Lifesciences Pvt. Ltd. / M/s Cipla Limited | 151.98 |
51 | Brinzolamide, Brimonidine Tartrate & Timolol Ophthalmic suspension | Each ml contains: Brinzolamide IP 10mg Brimonidine Tartrate IP 2 mg Timolol Maleate eq. to Timolol IP 5 mg Water for injection | 1 ml | M/s Micro labs Limited | 105.25 |
The notification further added,
(a)The manufacturer of above-mentioned formulations i.e., “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b)The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
(c)The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(d)As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(e)The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
(f)In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g)Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.
To view official notice click the link below:
https://www.nppaindia.nic.in/wp-content/uploads/2023/09/Retail-Engli.pdf
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd